Notes / Company

Haleos Labs Ltd.

HALEOSLABS BSE 540679 ISIN INE320X01016 Pharmaceuticals

Fundamentals

Market cap: ₹423 cr
P/E: 24.44×
ROE: 10.23%
Debt / equity: 0.43
Div yield: 0.10%
52-week range: 1067.00 — 1774.00

Research on Tijori Finance

Company snapshot

Haleos Labs Ltd.

Pharmaceuticals

₹438 cr

P/E 25.31×

Latest quarter · Mar 2026

Sales₹75 cr

Net profit₹0 cr

Op. margin+5.5%

EPS₹1.44

Strength & growth

Debt / equity0.43×

Current ratio1.06×

Sales CAGR+4.3%

EPS CAGR+13.5%

The timeline — 1 note on Haleos Labs Ltd.

May 2026

30 May 26 · 2:25 PM IST Brief

Brief · Earnings · Micro cap

Haleos Labs' profit shrank 17% on 10% revenue drop in FY26

Full-year standalone results confirm a contraction. A ₹1.50 dividend is the one positive amid the weaker earnings.

Verify on exchange BSE filings for HALEOSLABS NSE filings for HALEOSLABS Tijori Finance company page